Georgia Tech Research Corporation

University of California

University of Washington

Emory University

University of Massachusetts

Children's Healthcare of Atlanta, Inc.

Other

Georgia State University Research Foundation, Inc.

University of Rochester

Georgia State Research Foundation

Niren Murthy

Allan Sachs Hoffman

Patrick S Stayton

Xinghai Ning

Lawrence A Crum

David A Tirrell

Pierre D Mourad

Oliver Press

Tyrone M Porter

Barbara Dale Boyan

Christopher Douglas Hermann

Zvi Schwartz

Robert Guldberg

Chantal Lackey Reed

David Scott Wilson

Tamim Diab

Jean M J Frechet

Mark M Goodman

W Robert Taylor

Dorian Liepmann

Eric Seth Gilbert

Kiana Aran

Bryan Stubblefield

Kousik Kundu

Sarah F Knight

Jacobo Paredes

Lee W Riley

Abhinav Prakash Acharya

Irina M Conboy

Kunwoo Lee

Michael J Conboy

Elliot C Woods

Michael K Davis

Bali Pulendran

Jihua Hao

Joachim Justad Roeise

Chung Hak Taing

Chantal Lackey

Tara Renee BeBoer

Bora Park

Corinne Sadlowski

Stephen C Yang

Marcin Kwissa

Michael John Heffernan

Robert H Pierce

Sungmun Lee

Tara Renee DeBoer

Seungjun Lee

Michael J Heffernan

Marcin Emory University Kwissa

The present disclosure provides endosomal disruptors, which are useful for facilitating delivery of a macromolecule to the cytoplasm of a cell. The present disclosure provides compositions comprising an endosomal disruptor and a macromolecule. The present disclosure provides methods of delivering a macromolecule to the cytoplasm of a cell.

Compositions and methods for delivery of macromolecules

Provided are active agent delivery devices configured to deliver an active agent formulation into or through a mucosal layer in a subject. The active agent delivery devices include a power reservoir configured to eject the active agent formulation at a pressure sufficient to deliver the active agent formulation into or through a mucosal layer in a subject. Methods of using the subject active agent delivery devices are also provided.

Active agent delivery devices and methods of using the same

Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.

Polymer hydrogels for in vivo applications and methods for using and preparing same

Aspects of the present disclosure include antibacterial aromatic sulfonyl fluoride agents. The subject aromatic sulfonyl fluoride agents have a pharmacophore that can provide for potent antibacterial activity. The subject agents are compounds including an aromatic group substituted with a sulfonyl fluoride warhead group and an electron withdrawing group. The subject agents find use in a variety of antibiotic applications. In some cases, the subject agents find use in methods of treating bacterial infections in a subject. Also provided are pharmaceutical compositions and kits that find use in practicing the subject methods.

Aromatic 2-nitrosulfonyl fluoride antibiotics and methods of use thereof

Diagnostic assays and methods employ a dual-enzyme cascade system comprised of two enzymatic amplifiers and two molecular probes, by (a) incubating a target enzyme with a target enzyme substrate to liberate a thiol; (b) incubating the thiol with a disulfide inactivated amplification enzyme to activate the amplification enzyme in an interchange reaction of the thiol and the disulfide; and (c) incubating the activated amplification enzyme with an amplification enzyme substrate to generate an amplified signal.

Amplification technology using dual enzyme cascade detection

This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.

Oligosaccharide conjugates for targeting bacteria and uses related thereto

The present disclosure provides methods of reducing levels of lactate in a fluid or tissue in an individual. The present disclosure provides pharmaceutical compositions suitable for use in the methods.

Compositions and methods for reducing lactate levels

Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontopheresis, and/or electrophoresis can also be used with the disrupting agents.

Enhanced transport using membrane disruptive agents

The present disclosure is generally related to methods of preventing oxidative stress injury induced by renal ischemia-reperfusion by a Folate-TEMPOL conjugate.

Methods for preventing oxidative stress injury of a tissue by a Folate-TEMPOL conjugate

Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted &#x3c0; conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended &#x3c0; conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo.

Reduced dye probes for the detection of radical oxygen species

Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes (at physiologic pH, but can become active toward cell membranes if the environment is acidified below ca. pH 6.8), coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontopheresis, and/or electrophereis can also be used with the disrupting agents.

Growing community of inventors

Atlanta, GA, United States of America

Niren Murthy